Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T18:52:38.274Z.
Calculation as of: 2026-10-06T18:52:38.274Z.
Quote observation: 2026-10-06T18:48:58.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8dd4f1084baaf1fdd631c8004248db7003b46672aad8e0139030c30c223f55df
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$17.14M
EV/FCF Ratio
N/A
TTM Avg
2075.17x
3Y Avg
2570.19x
5Y Avg
2570.19x
Market Cap
$16.50M
EV/FCF Ratio
N/A
TTM Avg
47.06x
3Y Avg
54.97x
5Y Avg
55.49x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PAVmed Inc. (PAVM) | $17.14M | N/A | N/A | N/A | N/A |
| Palatin Technologies, Inc. (PTN)vs › | $17.14M | N/A | 2075.17x | 2570.19x | 2570.19x |
| Lipocine Inc. (LPCN)vs › | $17.07M | N/A | N/A | N/A | N/A |
| Marker Therapeutics, Inc. (MRKR)vs › | $16.84M | N/A | N/A | N/A | N/A |
| Bionano Genomics, Inc. (BNGO)vs › | $16.87M | N/A | N/A | N/A | N/A |
| TScan Therapeutics, Inc. (TCRX)vs › | $16.53M | N/A | N/A | N/A | N/A |
| Dyadic International, Inc. (DYAI)vs › | $16.50M | N/A | 47.06x | 54.97x | 55.49x |
| Cosmos Health Inc. (COSM)vs › | $17.84M | N/A | 14.44x | 40.11x | 40.11x |
| Estrella Immunopharma, Inc. (ESLA)vs › | $17.99M | N/A | N/A | N/A | N/A |
| BioCardia, Inc. (BCDA)vs › | $15.78M | N/A | 79.94x | 79.62x | 79.62x |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
